Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

v3.24.1.1.u2
Stockholders’ Equity (Details Narrative) - USD ($)
 3 Months Ended
Jun. 22, 2022
Jan. 23, 2022
Mar. 31, 2024
Mar. 31, 2023
Mar. 28, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Number of shares granted 1,498,128   893,181    
Number of additional granted shares issued     120    
Aggregate vested shares value     $ 2,009,657    
Number of unvested shares     15,181    
Unrecognized value of shares     $ 34,157    
Stock repurchase value     299,116    
Repurchase of common stock, shares       519,828  
Repurchase common stock value       $ 7,536,216  
Net proceeds from sale of shares     299,116  
Aggregate intrinsic value of outstanding warrants     257,269    
Closing share price         $ 19.94
Exercise price $ 7.63        
Stock granted     $ 9,512,356    
Risk-free interest rate     3.20%    
Voltality rate     106.00%    
Compensation expense     $ 4,221,106 $ 1,843,018  
Fair value     $ 5,291,250    
Vesting term     4 years    
At The Market Offering [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Number of shares issued     27,117    
Public offering price     $ 12.26    
Gross proceeds from sale of shares     $ 332,351    
Net proceeds from sale of shares     299,116    
Underwriting discount commission and offering expenses     $ 33,235    
Maximum [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Stock repurchase value   $ 10,000,000      
Common Stock [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Number of shares granted     908,362    
Common stock vested shares     0 0  
Stock repurchase value     $ 28